ASCO 2026: Bicara Therapeutics is presenting long-term follow up data at ASCO that it believes shows durability derived from choosing TGF-β with EGFR for its fusion protein in HPV negative head & neck
- May 31
- 1 min read
CEO Claire Mazumdar describes the ASCO data, and updates us on the phase 2/3 study, which is already in the phase 3 portion. Bicara hopes to use the study to eventually gain an accelerated approval.
.png){kind=logo}